Assertio Therapeutics, Inc.
Officielle registerdata
0følgere
2018grundlagt
Om Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
Hovedsæde251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Stiftet2018
StatusAktiv
Patenter1 patent
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
Anmeldelser
Ingen anmeldelser endnu. Har du arbejdet med Assertio Therapeutics, Inc.? Vær den første til at dele din oplevelse.
Juridiske oplysninger
| Juridisk navn | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20Vis på GLEIF ↗ |
| Registreret adresse | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| Status | Aktiv |
Kilder: GLEIF · opdateret 16. Oktober 2026
Kontakt og links
Sted
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Er det din virksomhed?
Gør krav på denne side gratis for at tilføje dit logo, produkter, billeder og job og for at svare på anmeldelser.
Gør krav på denne sideBliv en del af Heelky for at skabe forbindelse, ansætte og vokse
Opret en gratis konto for at skrive til folk, søge job og oprette opgaver.
Deltag nu — det er gratis